222. Primary nephrotic syndrome Clinical trials / Disease details

Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04009668 (ClinicalTrials.gov)	October 2, 2019	2/7/2019	Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	FSGS;MCD;Focal Segmental Glomerulosclerosis;Minimal Change Disease	Drug: adalimumab	University of Michigan	New York University	Recruiting	6 Years	70 Years	All	8	Phase 2	United States
2	NCT00814255 (ClinicalTrials.gov)	December 2008	22/12/2008	Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial	Novel Therapies for Resistant Focal Segmental Glomerulosclerosis	Focal Segmental Glomerulosclerosis	Drug: Adalimumab;Drug: Lisinopril , losartan, and atorvastatin;Drug: galactose	New York University School of Medicine	University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	1 Year	65 Years	All	32	Phase 2	United States;Canada
3	NCT00193648 (ClinicalTrials.gov)	July 2005	10/9/2005	Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)	Novel Therapies for Resistant FSGS	Focal Glomerulosclerosis	Drug: Rosiglitazone (Avandia);Drug: Adalimumab (Humira)	North Shore Long Island Jewish Health System	University of North Carolina;The Cleveland Clinic	Completed	2 Years	40 Years	Both	21	Phase 1	United States